摘要
目的探讨吸入沙美特罗/替卡松粉剂对慢性阻塞性肺病(COPD)稳定期患者血清内脂素(visfatin)浓度的影响。方法选择III级及IV级稳定期COPD患者84例,随机分为单纯吸入沙美特罗(50μg)及沙美特罗/替卡松粉剂(50μg/500μg)两组,每组42例,每日吸入2次,每次1吸,疗程8周。收集治疗前后血清标本各1份,采用ELISA法检测患者血清visfatin浓度。结果治疗前后平均血清visfatin浓度吸入沙美特罗/替卡松粉剂治疗组患者分别为(26.1±6.5)ng/ml和(17.2±5.3)ng/ml,治疗前后血清平均visfatin水平差异有统计学意义(P<0.05)。单纯吸入沙美特罗/粉剂组治疗前后患者血清visfatin浓度分别为(27.5±6.9)ng/ml和(26.7±6.5)ng/ml,治疗前后血清平均visfatin水平差异无统计学意义(P>0.05)。结论稳定期COPD患者吸入沙美特罗/替卡松粉剂治疗,血清visfatin浓度比治疗前降低,血清visfatin浓度检测可成为一个潜在的COPD治疗的生物学检测指标。
[Abstract] Objective To determine the effect of inhaled salmeterol/fluticasone on serum visfatin in individuals with stable chronic obstructive pulmonary disease. Methods 84 COPD patients were randomly divided ;.nto two groups. Group 1 （n=42） were treated with salmeterol （50μg） alone, and group 2 （n=42） with salmetero fluticasone（5Ovg/ 500vg）. Each patient inhaled twice daily and inhaled each day for 8 weeks. Serum samples were taken at baseline and 8 weeks after treatment. The levels of serum visfatin were detected in the method of ELISA. Results The average serum visfatin for patients were significantly decreased from 26.1±6.5ng]ml to 17.2±5.3ng/ml （P〈0. 05） in patients inhaled salmeterol/fluticasone. The average serum visfatin for patients inhaled salmeterol alone was 27.5±6.9ng/ml and 26.7±6.5ng/ml at baseline and after inhaled salmeterol were not difference（P〉0.05）. Conclusion The serum visfatin in patients with stable COPD inhaled salmeterol/fluticasone decrease significantly and may be a potential diagnostic biomarker for COPD treatment.
出处
《西部医学》
2014年第2期186-188,共3页
Medical Journal of West China
